Day: March 23, 2023

–     Milestone related to the launch of Cresemba in Japan Basel/Allschwil, Switzerland, March 23, 2023 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, announced today that its license partner Asahi Kasei Pharma (“AKP”) has reported the achievement of a milestone related to the launch of Cresemba® (isavuconazole) in Japan, which triggered a CHF 5 million payment from AKP to Basilea. David Veitch, Basilea’s CEO, stated: “We congratulate our partner AKP on this significant milestone, following the marketing authorization in Japan in December 2022. Japan is an important commercial market for newer antifungals and we look forward to continue working together with AKP to make Cresemba available to patients in Japan for...

Not For Dissemination in the United States or Through U.S. Newswire Services VANCOUVER, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) — TDG Gold Corp. (“TDG” or the “Company”) (TSXV:TDG), is pleased to announce that it has entered into an agreement with Raymond James Ltd. on behalf of a syndicate of agents (collectively, the “Agents”), pursuant to which the Agents agree to offer for sale on behalf of the Company on a reasonable “best efforts” basis up to 11,111,100 Charity Flow-Through Units (the “Charity Flow-Through Units”), at $0.45 per Charity Flow-Through Unit (the “Charity Flow-Through Unit Offering Price”), up to 3,333,300 hard dollar units (the “Hard Dollar Units”) at $0.30 per Hard Dollar Unit (the “Hard Dollar Unit Offering Price”) and up to 1,428,571 Flow-Through Shares (the “Flow-Through Shares”) at $0.35 per Flow-Through...

SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational product for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). On the question, “Is the available evidence sufficient to conclude that a reduction in plasma neurofilament light chain (NfL) concentration in tofersen-treated patients is reasonably likely to predict clinical benefit of tofersen for treatment of patients with SOD1-ALS?” the Committee voted unanimously yes (9 yes to 0 no), for consideration of a potential accelerated approval. On...

BELOIT, Wis. and BRAINTREE, Mass., March 22, 2023 (GLOBE NEWSWIRE) — Regal Rexnord Corporation (NYSE: RRX) (“Regal Rexnord”) and Altra Industrial Motion Corp. (Nasdaq: AIMC) (“Altra”) jointly announced today that they have received all required regulatory approvals to complete the previously announced acquisition of all of the issued and outstanding shares of common stock of Altra, whereby a wholly owned subsidiary of Regal Rexnord will be merged with and into Altra, with Altra surviving the merger as a wholly owned subsidiary of Regal Rexnord (the “Transaction”). The closing of the Transaction is expected to occur on or around March 27, 2023, subject to the satisfaction or waiver of the remaining closing conditions set forth in the merger agreement between the parties. Advisors J.P. Morgan and Incentrum Group are serving as financial...